Microcapsules containing a peptide having cell receptor binding ability and a cosmetic composition containing the same

Abstract

A peptide having cell receptor binding ability, a microcapsule linked to the above peptide, and a cosmetic composition containing the same are disclosed in this specification. The peptide according to an embodiment of the present invention has excellent selective binding ability to a target, and the physicochemical stability of the microcapsule is excellent. Therefore, the cosmetic composition containing the microcapsule combined with the above peptide has excellent delivery efficiency to the target cells of the active ingredient contained in the capsule and excellent skin condition improving effect.

Description

[0001] Divisional application.

[0002] Microcapsules containing peptides having cell receptor binding ability and cosmetic compositions containing the same Technical Field

[0003] This specification discloses a peptide having cell receptor binding ability, a microcapsule linked to the above peptide, and a cosmetic composition containing the same. Background Art

[0004] Microcapsules are basic technologies used in various fields such as pharmaceuticals, coatings, the electronics industry, and cosmetics. In particular, they are the best tools for maintaining the initial efficacy of active ingredients and have attracted much attention in the fields of pharmaceuticals and cosmetics (Journal of controlled release, 58, 9, 1999).

[0005] However, when a cosmetic composition containing the microcapsules discovered so far is applied to the human body, no significantly improved effect can be obtained compared to a cosmetic composition without microcapsules.

[0006] Accordingly, recently, technologies for delivering microcapsules to target cells have been continuously developed using the principle of drug delivery systems. However, what has been discovered so far is that due to problems such as the molecular instability of microcapsules and the binding force with target cells, satisfactory effects have not been obtained so far.

[0007] Prior Art Documents

[0008] (Patent Document 1) KR 10-1051557B1 Summary of the Invention

[0009] Technical Problems

[0010] In one embodiment, an object of the present invention is to provide a peptide having excellent binding force with target cells.

[0011] In one embodiment, an object of the present invention is to correctly and stably deliver an active ingredient to target cells.

[0012] In one embodiment, an object of the present invention is to provide a cosmetic composition in which the delivery force of an active ingredient to the skin is improved.

[0013] Solutions to the Problems

[0014] In one embodiment, the present invention provides a peptide having cell receptor binding ability, and the peptide is a peptide containing any one of the sequences of SEQ ID NOs: 1 to 3.

[0015] In one embodiment, the present invention provides a microcapsule having the above peptide linked to its surface.

[0016] Moreover, in one embodiment, the present invention provides a cosmetic composition comprising the above microcapsules.

[0017] Effects of the Invention

[0018] The peptide of one embodiment of the present invention has excellent selective binding ability to the target. Also, the microcapsules of one embodiment of the present invention have excellent physicochemical stability. Therefore, in a cosmetic composition comprising microcapsules combined with the above peptide, the delivery efficiency of the active ingredient contained in the capsules to target cells is excellent, and the effect of improving skin condition is excellent. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] FIG. 1 shows the results of confirming the binding ability of the capsules of the present invention to the target (target cells) ( Figure 1a : Capsule 1, Figure 1b : Capsule 2, Figure 1c : Capsule 3).

[0020] FIG. 2 is a graph showing the expression changes of collagen 1 ( Figure 2a ), collagen 2 ( Figure 2b ), and elastin ( Figure 2c ) when Capsule 1 of the present invention is treated.

[0021] Figure 3 FIG. 3 is a graph showing the improvement effect of eye wrinkles after using an ampoule containing the capsules of the present invention.

[0022] FIG. 4 is a graph showing the α-MSH binding inhibitory ability ( Figure 4a ) and melanin synthesis inhibitory ability ( Figure 4b ) when Capsule 2 of the present invention is treated.

[0023] Figure 5 FIG. 5 is a graph showing the whitening effect after using a lotion containing the capsules of the present invention.

[0024] FIG. 6 is a graph showing the expression changes of keratin 1 ( Figure 6a ), keratin 5 ( Figure 6b ), and filaggrin (FIG. 6C) when Capsule 3 of the present invention is treated.

[0025] Figure 7 FIG. 7 is a graph showing the improvement effect of the skin barrier (peridermal density, skin thickness) after using a nutrient cream containing the capsules of the present invention.

[0026] Figure 8 FIG. 8 is a schematic diagram showing microcapsules in which an excessive amount of hydrophilic bioactive substances of the present invention are stabilized on a multilayer structure formed by a lipid part.

[0027] Figure 9A figure showing a schematic diagram of a microcapsule containing a peptide.

[0028] Figure 10 A photograph of a concentrated composition sample manufactured by the intelligent encapsulation manufacturing technology of the present invention. Detailed Description of the Invention

[0029] Hereinafter, the present invention will be described in detail.

[0030] In one embodiment, the present invention is a peptide having cell receptor binding ability, and the peptide is a peptide containing any one of the sequences of SEQ ID NOs: 1 to 3.

[0031] In this specification, cell receptor binding ability refers to the ability to bind to a receptor formed on a cell.

[0032] The amino acid sequences of the peptides of SEQ ID NOs: 1 to 3 are as described in Table 1 below.

[0033] Table 1

[0034] Serial number Amino acid sequence 1 Ala-Lys-Ser-Thr 2 Glu-Gly-His-Lys-Ile-Phe-Pro-Ser-Trp-Tyr 3 Ala-Asp-Gly-Ser-Pro

[0035] In Table 1 above, Ala means alanine, Asp means aspartic acid, Glu means glutamic acid, Gly means glycine, His means histidine, Ile means isoleucine, Lys means lysine, Phe means phenylalanine, Pro means proline, Ser means serine, Trp means tryptophan, Tyr means tyrosine, and Thr means threonine.

[0036] In one embodiment, the cells targeted by the above peptide may include melanocytes, keratinocytes, or fibroblasts.

[0037] Furthermore, the above cell receptors may include fibroblast growth factor receptors, integrin receptors, or melanocortin receptors. Specifically, the above melanocortin receptor may be melanocortin 1 receptor (MC1R).

[0038] In one example, the peptide of SEQ ID NO: 1 targets fibroblasts and can bind to fibroblast growth factor receptors.

[0039] And, in one example, the peptide of SEQ ID NO: 2 targets melanocytes and can bind to melanocortin receptors.

[0040] Also, in one example, the peptide of SEQ ID NO: 3 targets keratinocytes and can bind to integrin receptors, particularly to the β1 family of integrin receptors.

[0041] In one embodiment of the present invention, the above peptide does not bind to other cells other than the target cells or their receptors. Due to its excellent binding ability, when the linking peptide is linked to other components, high delivery ability to the target can be expected.

[0042] In one embodiment, the present invention is a microcapsule with the above peptide linked on its surface. The above peptide binds to the hydrophilic group on the microcapsule. For example, it binds to the carboxyl group and the N-terminus of the peptide and can be linked to the microcapsule. However, the linking method is not limited and can be carried out according to various methods known to those of ordinary skill in the art.

[0043] The microcapsule can contain a wide variety of polymers, including these polymers, thermosensitive polymers, photosensitive polymers, magnetic polymers, pH-sensitive polymers, salt-sensitive polymers, chemically sensitive polymers, polyelectrolytes, polysaccharides, peptides, proteins, and / or plastics, but not limited thereto. Polymers include substances such as poly(N-isopropylacrylamide) (PNIPAAm), poly(styrene sulfonate) (PSS), poly(allylamine) (PAAm), poly(acrylic acid) (PAA), poly(ethyleneimine) (PEI), poly(diallyldimethylammonium chloride) (PDADMAC), poly(pyrrole) (PPy), poly(vinylpyrrolidone) (PVPON), poly(vinylpyridine) (PVP), poly(methacrylic acid) (PMAA), poly(methyl methacrylate) (PMMA), polystyrene (PS), poly(tetrahydrofuran) (PTHF), poly(phenylenediamine) (PTHF), poly(hexyl viologen) (PHV), poly(L-lysine) (PLL), poly(vinyl alcohol) (PVA), poly(L-arginine) (PARG), poly(lactic-co-glycolic acid) (PLGA), etc., but not limited thereto.

[0044] In one example, the above capsule can be double-layered. In this case, the outer layer can contain polyvinyl alcohol, and the inner layer can contain poly(lactic-co-glycolic acid) (PLGA).

[0045] Also, the microcapsule can contain one or more substances that can generate effective neutral, negative, or positive charges on the outer layer of the capsule. In some cases, the charge of the capsule can help prevent or promote the aggregation or clustering of particles.

[0046] In one embodiment, based on the total cross-sectional area of the microcapsule, the above peptide can be present at 0.1 - 10 peptides / μm 2The density of the above-mentioned peptide preferably can be 0.3 to 8 peptides / μm 2 , and most preferably can be 0.4 to 7 peptides / μm 2 . The density of the peptide can mean the number of peptides present based on the unit surface area of the microcapsule.

[0047] For example, when the density of the peptide on the above-mentioned microcapsule is less than 0.1 peptides / μm 2 , or greater than 10 peptides / μm 2 , it presents a skin state improvement effect similar to that of microcapsules not connected to peptides, and has excellent binding force to target cells and effective ingredient delivery force to target cells within the above density range.

[0048] In one embodiment, the above-mentioned microcapsule further contains an active ingredient encapsulated in the capsule. The active ingredient can include: amino acids; plant-derived proteins or their hydrolysates; and one or more of yeast fermentates, their lysates or their filtrates. And, as the active ingredient encapsulated in the capsule, various plant extracts and their fruit extracts can be included. Specifically, the above-mentioned plant extracts can include narcissus bulb extract, snowflake lily bulb extract, etc., and the fruit extract can include pitaya extract.

[0049] And, the above-mentioned amino acids are not limited and can include arginine, alanine, glutamine, glycine, isoleucine, leucine, lysine, histidine, proline, tyrosine, serine, valine, phenylalanine, tryptophan, threonine, aspartic acid, etc.

[0050] In one example, the above-mentioned plant-derived protein can include lupin protein, and the above-mentioned yeast can include Pichia pastoris. In one example, the above-mentioned yeast fermentate can be a Pichia fermentation lysate filtrate.

[0051] In the above aspect, the plant-derived protein or its hydrolysate and the yeast fermentate, its lysate or its filtrate can each be included in an amount of 0.0001 to 30% by weight based on the total weight of the active ingredient. When less than 0.0001% by weight, the effect is very small, and when greater than 30% by weight, there will be stability problems such as discoloration and off-flavor. The above-mentioned plant-derived protein or its hydrolysate; yeast fermentate; and its lysate or its filtrate can each preferably be included in an amount of 0.01 to 30% by weight, and more preferably in an amount of 0.01 to 25% by weight based on the total weight of the active ingredient.

[0052] The above amino acids may be contained in an amount of 0.00001 to 0.1% by weight, preferably in an amount of 0.0001 to 0.1% by weight, more preferably in an amount of 0.0001 to 0.05% by weight, and the above plant extract or fruit extract may be contained in an amount of 0.0001 to 30% by weight. The above plant extract and fruit extract may preferably be contained in an amount of 0.001 to 20% by weight, and most preferably in an amount of 0.001 to 15% by weight.

[0053] When the content of the amino acids is less than 0.00001% by weight, the efficacy is very low, and when it is greater than 0.1% by weight, there will be problems with the viscosity stability of the dosage form.

[0054] When the plant extract and fruit extract are less than 0.0001% by weight, the effect is very low, and when it is greater than 30% by weight, there will be problems with discoloration, off-flavor, and viscosity stability of the dosage form.

[0055] When the components arranged above are contained within the above content range, the best moisturizing, skin barrier strengthening, whitening, wrinkle improvement, and skin elasticity improvement effects can be obtained.

[0056] In one embodiment, the present invention is a cosmetic composition containing the above microcapsules. The above composition may be for moisturizing, skin barrier strengthening, whitening, wrinkle improvement, or skin elasticity improvement.

[0057] In this specification, skin barrier strengthening may mean promoting the differentiation of skin keratinocytes, strengthening the outermost layer of the skin, and improving the skin condition.

[0058] In one embodiment, the above composition may promote the synthesis of keratin 1, keratin 5, keratin 10, keratin 14, filaggrin, loricrin, elastin, collagen, etc.

[0059] In one embodiment, the content of the microcapsules in the above cosmetic composition may be 0.0001 to 30% by weight, preferably 0.001 to 20% by weight, and most preferably 0.01 to 10% by weight.

[0060] When the content of the microcapsules in the cosmetic composition is less than 0.0001% by weight, the effect is very low, and when it is greater than 30% by weight, the dispersion of the capsules in the composition decreases, and the viscosity of the cosmetic composition will be lost.

[0061] Hereinafter, the present invention will be described through production examples and examples. The following production examples and examples are only for illustrating the present invention, and should not be construed as limiting the scope of the rights of the present invention thereto.

[0062] [Production Example]

[0063] [Production Example 1] Production of Peptides

[0064] The peptides with serial numbers 1 to 3 in Table 1 above were synthesized by the FMOC solid-phase method using an automated synthesizer (PeptrEx-R48, Peptron Inc., Daejeon, Korea). The synthesized peptides were purified and analyzed by reverse-phase high performance liquid chromatography (RP-HPLC) using an RP column (Shiseido Capcell Pak) (Prominence LC-20AB, Shimadzu Corporation, Japan), and identified using a mass analyzer (HP 1100 Series LC / MSD, Hewlett-Packard Company, Roseville, USA).

[0065] [Production Example 2] Production of Microcapsules

[0066] [Production Example 2-1] Production of Peptide-Unattached Microcapsules

[0067] The lipid concentration part (ceramide, cholesterol, hydrogenated lecithin) was put into an additional dissolution tank and dissolved by heating at 70°C. The hydrophilic physiologically active substance part (panthenol, raffinose, niacinamide, green tea water) was put into an additional dissolution tank and dissolved by heating at 45°C for standby. Then, the prepared lipid concentration part was put into the dissolution tank equipped with the lipid stabilizing part. While maintaining the temperature at 50°C, it was stirred at a speed of 1500 rpm for 5 minutes using an agitator, and the hydrophilic physiologically active substance part was added. It was stirred at a speed of 1500 rpm for 5 minutes using an agitator and homogenized to prepare a first concentrated phase in which the excessive hydrophilic active ingredient was homogenized in a bulky manner. Then, the above first concentrated phase was maintained at a temperature of 50°C and stirred at a low speed of 500 rpm for 1 hour using an agitator to fully hydrate the first concentrated phase. Then, at 50°C, the hydrated first concentrated phase was put into a high-pressure emulsifier and treated at a pressure of 9000 Pa twice, so that the excessive hydrophilic physiologically active substance was located in the aqueous phase between the aqueous phase formed in the innermost phase and the lipid bilayer, and was concentrated and encapsulated in a nanosize to form a second concentrated phase. Then, at 28°C, it was slowly stirred at a speed of 500 rpm in an agitator and cooled to be stabilized to produce microcapsules in a peptide-unbound state. The diameter of the produced microcapsules was about 0.2 micrometers.

[0068] [Production Example 2-2] Production of Peptide-Attached Microcapsules

[0069] Attach the peptide of Production Example 1 to the microcapsules produced in Production Example 2-1.

[0070] Connect the N-terminus of the peptide to the carboxyl group on the surface of the microcapsules in the peptide-unbound state, and attach the peptide of Production Example 1 to the surface of the microcapsules respectively. Specifically, resuspend the peptide-unbound microcapsules in 2-(N-morpholino)ethanesulfonic acid (MES) buffer (MES buffered saline, pH 5.5), and react with 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDAC) and N-Hydroxysuccinimide (NHS) for about 1 hour. Then, centrifuge the microcapsules at about 15,000 rpm for 1 hour to remove EDAC and NHS, and activate the surface of the peptide-unbound microcapsules. Then, suspend the microcapsules in about 100 ml of phosphate-buffered saline (PBS), and react about 0.1 g of the peptide of SEQ ID NO: 1 with the microcapsules at room temperature. Then, wash with PBS buffer to remove the unreacted peptide. The peptides of SEQ ID NO: 2 and 3 are also produced into microcapsules connected to the peptide by adjusting the dosage of the reagent in the same method as above. Confirm whether the peptide is attached to the microcapsules by ninhydrin detection (Kaiser test). And, using a scanning electron microscope (JSM-7100F), measure the density of the peptide on the surface of the microcapsules, showing a density of approximately 2 peptides / μm 2 of density.

[0071] The microcapsules connected to the peptide of SEQ ID NO: 1 are Capsule 1, the microcapsules connected to the peptide of SEQ ID NO: 2 are Capsule 2, and the microcapsules connected to the peptide of SEQ ID NO: 3 are Capsule 3.

[0072] [Production Example 3] Regulation of Peptide Density on Microcapsules

[0073] Produce microcapsules in the same way as in Production Example 2, and regulate the peptide density in the microcapsule phase by adjusting the dosage of the peptide. Divide the experimental groups as follows according to the density.

[0074] Table 2

[0075]

[0076] [Examples]

[0077] [Example 1] Cytotoxicity Test

[0078] The B16 melanoma cells were treated with each 10 μM of Capsules 1-3, and the cell viability was confirmed. As a control group, kojic acid and arbutin were treated. As a result, when the capsules of the present invention were treated, the cell viability hardly changed, and thus it was confirmed that there was no cytotoxicity.

[0079] [Example 2] Binding selectivity test with target cells

[0080] In order to confirm whether each of Capsules 1-3 binds to other cells in addition to the target cells, it was confirmed whether they bind to a variety of cells. As a result, it was confirmed that Capsules 1 to 3 hardly bind to cells other than each target cell.

[0081] [Example 2-1] Capsule 1

[0082] By fluorescence immunoassay and using flow cytometry (FACS), the binding ability of Capsule 1 to cells was confirmed. The cells used were fibroblasts, keratinocytes, lymphocytes, monocytes, melanocytes, dendritic cells, and skin neurons. From the measurement results, it was confirmed that the binding rate of Capsule 1 to fibroblasts as target cells was about 75%, and in contrast, the binding ability to cells other than the target cells was significantly low ( Figure 1a ).

[0083] [Example 2-2] Capsule 2

[0084] The same experiment as in Example 2-1 was also performed on Capsule 2. As a result, it was confirmed that Capsule 2 exhibited a binding ability of about 70% to melanocytes as target cells, and in contrast, the binding rate to other cells was significantly low ( Figure 1b ).

[0085] [Example 2-3] Capsule 3

[0086] The same experiment as in Example 2-3 was also performed on Capsule 3. As a result, it was confirmed that Capsule 3 exhibited a binding rate of about 85% to keratinocytes as target cells, and in contrast, the binding rate to other cells was significantly low ( Figure 1c ).

[0087] [Example 3] Anti-aging effect of microcapsules linked to peptides (Capsules 1-3)

[0088] [Example 3-1] Binding force between fibroblasts and capsules (comparing the binding force according to the presence of peptides)

[0089] Compare the binding force between microcapsules with peptides linked to the capsule surface and microcapsules without linked peptides and fibroblasts, and the absorption of active ingredients.

[0090] At 4°C, culture Capsule 1 with target cells for 1 hour. After delaying the binding process, measure the binding force between microcapsules with peptides linked to the capsule surface and microcapsules without linked peptides and fibroblasts. The binding force between Capsule 1 and fibroblasts is about 4 times better than that of microcapsules without linked peptides.

[0091] [Example 3-2] Comparison of collagen and elastin production capacity

[0092] React microcapsules with peptides linked to the capsule surface with fibroblasts, and observe the production amounts of elastin and collagen.

[0093] When using capsules without linked peptides, the production amount of collagen is very small. On the contrary, when using Capsule 1 with linked peptides, the production amounts of Collagen Type 1 and 3 increase by about 1.7 times compared to capsules without linked peptides ( Figure 2a , Figure 2b ).

[0094] Regarding the production amount of elastin, after reacting the capsules for 7 days, Capsule 1 combined with peptides shows an elastin production amount more than 9 times greater than that of capsules without linked peptides ( Figure 2c ).

[0095] [Example 3-3] Skin wrinkle improvement evaluation test

[0096] Manufacture ampoules containing 30 wt% of Capsule 1 relative to the total weight. For 21 women aged 35 to 65 without skin diseases, evenly apply the above ampoules to the entire face, and apply them twice a day for 28 days to confirm the improvement degree of crow's feet wrinkles. As a result, it can be confirmed that there is an improvement effect of about 10% on crow's feet wrinkles ( Figure 3 ).

[0097] [Example 4] Whitening effect of microcapsules with linked peptides (Capsule 2-3)

[0098] [Example 4-1] Binding inhibition ability between melanocytes and α-MSH

[0099] Treat 10 μM each of microcapsules with peptides linked to the capsule surface (Capsule 2) and microcapsules without linked peptides respectively, and measure the binding force between melanocytes and α-melanocyte stimulating hormone (MSH). As a result, it can be seen that when using Capsule 2, the binding force between melanocytes and α-MSH is reduced by more than 95%Figure 4a )。

[0100] [Example 4-2] Melanin synthesis inhibitory ability

[0101] 10 μM each of the microcapsules with a peptide linked to the surface of the capsule and the microcapsules without the linked peptide were treated separately, and the amount of melanin synthesis was compared. As a result, when using Capsule 2, the amount of melanin produced by melanocytes was significantly reduced ( Figure 4b )。

[0102] [Example 4-3] Skin whitening effect evaluation test

[0103] Twenty-one women aged 35 to 55 without skin diseases evenly applied a lotion containing 15% Capsule 2 to the entire face, and applied it twice a day for 14 days to confirm the whitening effect. As a result, when applying the lotion containing Capsule 2, a significantly improved whitening effect was confirmed ( Figure 5 )。

[0104] [Example 5] Skin barrier improvement effect of microcapsules with linked peptides (Capsule 3-3)

[0105] [Example 5-1] Keratin 1 and keratin 5 and expression promotion effect

[0106] To observe the skin barrier improvement effect of Capsule 3 with a linked peptide, an effect of promoting the expression of keratin was observed. 10 μM each of the microcapsules with a peptide linked to the surface of the capsule and the microcapsules without the linked peptide were treated separately, and the expression levels of the above factors were confirmed. As a result, when using Capsule 3, the expression levels of keratin 1 and keratin 5 were about 2 times higher than those of the capsules without the linked peptide (in order, Figure 6a , 6b )。

[0107] [Example 5-2] Filaggrin synthesis promotion effect

[0108] The capsules were treated by the same method as in Example 5-1, and the filaggrin synthesis effect was confirmed. As a result, when using Capsule 3, an about 5-fold filaggrin expression level was confirmed compared with the case of the capsules without the linked peptide ( Figure 6c )。

[0109] [Example 6] Skin barrier strengthening effect evaluation test

[0110] Twenty women aged 35 to 55 without skin diseases evenly applied a nutrient cream containing 20% Capsule 3 to the entire face, and applied it twice a day for 14 days to confirm the density around the dermis and the skin thickness. As a result, when applying the nutrient cream containing Capsule 3, the density around the dermis and the skin thickness were significantly improved, and thus the skin barrier improvement effect was confirmed ( Figure 7 )。

[0111] [Example 7] Effect Difference Based on Peptide Density

[0112] For the experimental groups described in Table 2, the experiments of Examples 3 to 6 were carried out in the same manner. When the effect was 10 when capsules 1-3, 2-3, and 3-3 were included (density was 2 peptides / μm 2 ), the results of each experimental group were represented by the relative values of capsules 1-3, 2-3, and 3-3.

[0113] Table 3 records the experimental result values corresponding to the experiment of Example 3, Table 4 records the experimental result values corresponding to Example 4, and Table 5 records the experimental result values corresponding to Example 6.

[0114] Table 3

[0115]

[0116] Table 4

[0117]

[0118]

[0119] Table 5

[0120]

[0121] It can be seen from the results that when the density of the peptide exceeds the range of 0.1 to 10 peptides / um 2 , the effect of improving the skin condition is very small.

[0122] [Formulation Example]

[0123] [Formulation Example 1] Toner (for highlighter)

[0124] Table 6

[0125]

[0126]

[0127] [Formulation Example 2] Ampoule (for anti-aging) Table 7

[0128]

[0129]

[0130] [Formulation Example 3] Essence (for anti-aging) Table 8

[0131]

[0132] [Formulation Example 4] Eye Cream (for anti-aging) Table 9

[0133]

[0134]

[0135] [Formulation Example 5] Emulsion (for elasticity) Table 10

[0136]

[0137] [Formulation Example 6] Nutritional Cream (for elasticity) Table 11

[0138]

[0139]

[0140] Sequence Listing Free Text

[0141] Sequence number 1 (Ala-Lys-Ser-Thr) is the sequence of a peptide targeting fibroblasts. The peptide of sequence number 1 can bind to fibroblast growth factor receptors.

[0142] Sequence number 2 (Glu-Gly-His-Lys-Ile-Phe-Pro-Ser-Trp-Tyr) is the sequence of a peptide targeting melanocytes. The peptide of sequence number 2 can bind to melanocortin receptors.

[0143] Sequence number 3 (Ala-Asp-Gly-Ser-Pro) is the sequence of a peptide targeting keratinocytes. The peptide of sequence number 3 can bind to integrin receptors, especially to the β1 family of integrin receptors.

Claims

1. A peptide having cell receptor binding ability, characterized in that, The peptide consists of the sequence of SEQ ID NO:

2.

2. A microcapsule, characterized in that, The peptide according to claim 1 is attached to the surface.

3. The microcapsule according to claim 2, characterized in that, The peptide is included at a density of 0.1 to 10 peptides / μm based on the total cross-sectional area of the microcapsule. 2 .

4. The microcapsule according to claim 2, wherein the microcapsule further contains an active ingredient encapsulated therein, the active ingredient includes one or more of amino acids; plant-derived proteins or their hydrolysates; yeast fermentates, their lysates or their filtrates; and plant extracts.

5. The microcapsule according to claim 4, wherein the plant-derived protein includes lupin protein, the yeast includes Pichia pastoris.

6. The microcapsule according to claim 4, wherein the amino acids can be included in an amount of 0.00001 to 0.1% by weight based on the total weight of the active ingredient, the plant-derived protein or its hydrolysate, yeast fermentate, its lysate or its filtrate, and plant extract are each included in an amount of 0.0001 to 30% by weight based on the total weight of the active ingredient.

7. A cosmetic composition, characterized in that, The microcapsule according to claim 2 is included.

8. The cosmetic composition according to claim 7, characterized in that, The cosmetic composition is for whitening.

Images